Related Experiment Videos
Erlotinib-induced pustular eruption
F Cusano1, G Ferrara, E Barletta
1Unit of Dermatology, G. Rummo Hospital, Benevento, Italy. francesco.cusano2@tin.it
Abstract:
The epidermal growth factor receptor (EGFR) inhibitor erlotinib was found to significantly improve overall survival, time to progression, and cancer-related symptoms in locally advanced or metastatic non small cell lung carcinoma (NSCLC). Unfortunately, cutaneous side effects are not rare, the most common one being a follicular acneiform eruption. As it has been observed a positive correlation between rash severity and objective tumor response, it is critical for dermatologists early distinguish it from rashes carrying a different prognosis and needing a different management.
Related Concept Videos
Drug Toxicity: Allergic Reactions
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...